Acrivon Therapeutics, Inc. Common Stock / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €0.00 +NaN% -€69.49M +33.4% N/A -€54.26M +52.1% N/A
    €0.00 +NaN% -€52.09M +103.5% N/A -€35.67M +47.9% N/A
    €0.00 +NaN% -€25.60M +82.7% N/A -€24.11M +103.4% N/A
    €0.00 +NaN% -€14.01M +206.1% N/A -€11.86M +393.0% N/A
    €0.00 -€4.58M N/A -€2.40M N/A

    Notifications